Gain-of-function mutations of membrane receptor tyrosine kinase KIT especially gate-keeper D816V point mutation in KIT render kinase auto-activation, disease progression, and poor prognosis. D816V KIT is found in ∼80% of the patients of systemic mastocytosis (SM), and is resistant to the first and the second generations of tyrosine kinase inhibitors (TKIs). The purpose of this investigation was aimed at exploring whether ponatinib (AP24534), a novel effective TKI against T315I Bcr-Abl was active against D816V KIT. We discovered that ponatinib abrogated the phosphorylation of KIT harboring either V560G (sensitive to imatinib) or D816V mutation (resistant to imatinib) and the downstream signaling transduction. Ponatinib 
Introduction
Mastocytosis is an orphan, mostly sporadic diseases, characterized by abnormal accumulation of mast cells and activation of mast cells in various organs, involving bone marrow, skin, liver, and gastrointestinal tract (1) . Systemic mastocytosis (SM) and cutaneous mastocytosis constitute two major forms of mastocytosis. The clinical course in SM patients ranges from indolent and asymptomatic to a highly aggressive disease course, even mast cell leukemia (MCL) (1) . Acquired activating mutations in KIT (e.g. D816V, D816Y and D816F) have been identified in most patients with mastocytosis (1) . Currently, interferon-Į (2) and cladribine (2CdA) constitute the treatments of choice for the first line therapy in SM, however, with inadequate degree and duration of response (3) . Imatinib has been approved by U.S. Food and Drug Administration (FDA) for adult SM patients without the KIT D816V mutation (4).
Other TKIs dasatinib (5), midostaurin (PKC412) (6) , semaxinib (7) and EXEL-0862 (8) have been reported to exhibit growth inhibitory and apoptosis induction effects in mast cells harboring D816V KIT mutation. Although Ustun C et al reported that dasatinib has efficacy in SM-AML patients bearing D816V KIT, a phase II study from an independent group did not support the potency of dasatinib against D816V KIT (9) .
Midostaurin (PKC412) has synergistic effect with dasatinib to inhibit the growth of neoplastic mast cells (6, 10) , the long-term benefit of PKC412 has not yet been determined. Therefore, to develop novel effective drugs to treat aggressive SM and MCL is still needed.
KIT is a transmembrane receptor tyrosine kinase for stem cell factor (SCF) (11) . On stimulation of SCF, KIT undergoes phosphorylation at Y568 and Y570 residues and to activate various signaling pathways (12) . Gain-of-function mutations in KIT also lead to KIT activation and gives rise to uncontrolled cell growth, cell survival and apoptosis resistance (13) . Imatinib inhibits activation of wild-type KIT and some point mutant KIT (e.g. V560G) but not D816V by competitively occupying KIT enzymatic ATP binding pocket. Unfortunately, the kinase domain mutant D816V KIT counting for ~80% of all patients with SM is resistant (14) . Additionally, KIT mediates tyrosine phosphorylation and nuclear localization of ȕ-catenin which is an important component of Wnt/ȕ-catenin signaling pathway in mast cell leukemia (15, 16) . The ȕ-catenin accumulates in cytoplasm and transfers to nucleus where it engages TCF/LEF transcription factors for genes transcription (17) .
Ponatinib (AP24534), a potent multi-targeted kinase inhibitor (18) , has been approved by FDA to treat imatinib-resistant patients with chronic myelogenous leukemia including those harboring the gate-keeper mutant T315I Bcr-Abl (19, 20) .
Besides, ponatinib also manifests inhibitory activity towards PDGFR, KIT, as well as FGFR (21, 22) . Although it has been reported that ponatinib is active against BaF3 cells stably expressing Y823D KIT in vitro (22) and D816V KIT-positive mast neoplastic cells (10) , the in vivo effect remains to be examined.
In this report, our purpose was to validate the inhibitory effect of ponatinib against the mutant KIT cells and the in vivo antineoplastic efficacy in mouse models bearing cells with mutant KIT. We found that ponatinib inhibited the growth of 
Materials and Methods

Reagents and antibodies
Ponatinib (purity>95%, HPLC) was synthesized in our lab, prepared as a 20 mM stocking solution in dimethyl sulfoxide (DMSO) and stored in aliquots at -20 .
Imatinib mesylate was a product of Novartis Pharmaceuticals (23) . Z-DEVD-fmk (caspase 3 inhibitor) was purchased from BD Biosciences (San Jose, CA). MG132 described previously (27) . The primers of KIT were listed in Supplementary Table S1 .
Preparation of cell lysates
Total cell lysates were prepared in RIPA buffer. For detection of AIF and cytochrome c, cytosolic fraction was prepared with digitonin extraction buffer (28) .
Extracts of subcellular cytoplasmic, mitochondrial and nuclear fractions were separated as previously described (23) .
Real-time quantitative RT-PCR
Total mRNA was extracted with TRIzol reagent (Invitrogen), then reverse-transcribed into first-strand complementary DNA (cDNA) with maxima first strand cDNA synthesis kit (Thermo Fisher), followed by real-time quantitative PCR with the SYBR Premix Ex Taq kit (TaKaRa) according the protocol described previously (23) .The primers were shown in Supplementary Table S1. Each PCR reaction was in a 20-ȝl volume on a 96-well plate in Roche LightCycler480.
Cell viability assay
The MTS assay (CellTiter 96 Aqueous One Solution reagent; Promega, Shanghai, China) was used to evaluate cell viability as described previously (23, 28 
Apoptosis assay by flow cytometry
Apoptosis was measured using annexin V-fluoroisothiocyanate (FITC) and propidium iodide (PI) (Sigma-Aldrich, Shanghai) and analyzed with a FACScalibur flow cytometer and CellQuestPro software as described (8, 23) .
Colony formation assay
Human mast cell lines were initially treated with ponatinib at 1.0∼100 nM for 24 hours, harvested and washed with PBS, and subsequently seeded in methylcellulose medium (Methocult H4434, STEMCELL Technologies, Vancouver, Canada) following the manufacturer's instructions. One week later, the number of colony-formation units was evaluated with microscope according to the standard criteria (28) . following the manufacturer's instructions (25) . The cells were then exposed to ponatinib and subjected to cell death assay and Western blotting analysis.
Immunofluorescence staining HMC-1.2 cells were grown with 0.3 ȝM of ponatinib for 24 hours.
Immunofluorescence staining was carried out as previously reported (8) .
Assay of intracellular active β-catenin with flow cytometer
Ponatinib treated HMC-1.2 cells were harvested, fixed in 4% formaldehyde for 10 minutes at 37 , permeablilized in pre-chilled 90% methanol 30 minutes on ice.
After washing and blocking, the cells were stained with anti-active-ȕ-catenin, followed by flow cytometer analysis after staining with the secondary antibody Alexa Fluor 488-conjugated goat anti-mouse IgG. FITC-conjugated mouse IgG1 ț isotype control was stained the same way except the secondary antibody and evaluated the background fluorescence (29) .
Dual-luciferase reporter assay
The TCF/LEF reporter plasmid, pTOP-flash, and its mutant control, pFOP-flash were purchased from EMD Millipore (Billerica, MA). The Renilla luciferase reporter construct, pRL-TK, was purchased from Promega (Madison, WI). The dual-luciferase reporter assay was performed according to the manufacturer's instructions (Promega, 
Detection of mastocytoma cells by flow cytometry
The mononuclear cells were prepared from spleens of ASL/MCL mice as previously described (25, 29) . The cells were stained with anti-CD45-FITC and anti-CD117-PE, followed by analysis with a FACSCalibur flow cytometer. All experiments were performed at least 3 times, and data are exhibited as mean±95% confidence intervals. Comparisons between 2 groups were analyzed by t test while between more than 2 groups by one-way ANOVA with post-hoc comparison by Tukey's test unless otherwise stated. GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) was used for statistical analysis. P<0.05 was considered statistically significant.
Statistical analysis
on
Results
Ponatinib abolishes the phosphorylation of KIT and its downstream target molecules
We first analyzed the effect of ponatinib (Fig. 1A) on the phosphorylation of KIT at Y568/570 residues, and its downstream signaling (Stat3/5, Akt, Erk1/2). Our results showed that ponatinib potently inhibited the phosphorylation of KIT in both dose-and time-dependent manners (Fig. 1B) . However, ponatinib did not alter the levels of total protein and mRNA in KIT as detected with Western blotting analysis and qRT-PCR, respectively (Fig. 1B, C) . Ponatinib decreased the level of phosphorylated KIT in P815 cells (Fig. 1D) . Correspondingly, ponatinib dose-and time-dependently inhibited the phosphorylation of Stat3, Stat5, Akt, and Erk1/2 which are downstream targets of KIT (Fig. 1E) . Taken together, these results suggest a strikingly inhibitory effect of ponatinib on KIT signaling.
Ponatinib inhibits the growth of mast cells harboring D816V KIT
We next determined the effect of ponatinib on the growth of the mast cells. The presence of D816V mutation in KIT leads to resistance to imatinib (14) . We confirmed the differential sensitivity of HMC-1.1 cells and HMC-1.2 cells to imatinib, with IC 50 values of 1.1 ȝM vs. > 20 ȝM (Fig. 2A) . In contrast, ponatinib significantly inhibited the growth of both imatinib-resistant HMC-1.2 and -sensitive HMC-1.1, with IC 50 values of 165 nM and 143 nM, respectively ( Fig. 2A) . Furthermore, ponatinib inhibited the viability of the murine P815 cells at an IC 50 of 72 nM ( Fig.   2A ).
Because simultaneously inhibiting a specific tyrosine kinase and its downstream targets such as mTOR usually results in synergism (31, 32), we examined the effect of the combination between ponatinib and rapamycin, an mTOR inhibitor, in human mast cells. The results assessed by MTS assay after 72 hours of incubation in a serially diluted mixture at a fixed ratio revealed synergism between ponatinib and rapamycin based on the combination index (CI) (Fig. 2B) (28) .
To evaluate the impact of ponatinib on anchorage-independent growth of the mast cells, we performed the colony formation assay in methylcellulose. Mast cells were exposed to increasing concentrations of ponatinib for 24 hours and then assayed for colony formation in drug-free culture. Ponatinib potently inhibited the colony formation in methylcellulose in a dose-dependent manner (Fig. 2C) .
Ponatinib induces apoptosis in mast cells harboring D816V KIT by triggering release of cytochrome c and apoptosis-inducing factor
We evaluated the capability of ponatinib to induce apoptosis with flow cytometry. Ponatinib induced significantly increased cell death in both imatinib-sensitive HMC-1.1 cells and -resistant HMC-1.2 cells to a similar degree (~55% vs. ~65%) (Fig. 3A) .
Western blotting analysis showed that ponatinib dose-and time-dependently induced specific cleavage of PARP, caspase 8, 9 and 3 in the malignant mast cells (Fig.   3B ), further confirmed the occurrence of apoptosis with activation of these caspases.
Of note, when detecting cytochrome c and apoptosis-inducing factor (AIF) in the cytosolic fraction, their levels were increased as early as 12 hours after 0.3 ȝM ponatinib treatment (Fig. 3C) , which obviously preceded the activation of caspase 9, and caspase 3. These results suggested that ponatinib might lead to damage of mitochondria and trigger intrinsic pathway of apoptosis.
Effect of ponatinib on the expression of apoptosis-related proteins
To figure out the mechanism of ponatinib-induced apoptosis, we examined the expression of apoptosis-related proteins. Western blotting analysis in both mast cell lines indicated a decrease in levels of Mcl-1 and Bcl-2 in a dose-and time-dependent fashion, with no alteration in levels of Bcl-X L , Bax, Bim or Survivin (Fig. 3D) . (Fig. 4D) , although the activity of caspase 3 was inhibited, implying that the ponatinib-mediated decrease in
Mcl-1 plays a significant role in ponatinib-induced apoptosis
Mcl-1 was caspase 3-independent, and might be via a yet unknown mechanism.
Ponatinib abrogates Wnt/ȕ-catenin pathway in mast cells harboring D816V KIT
Wnt/ȕ-catenin pathway promotes the hematopoietic malignancy (35) . Tyrosine residue phosphorylation at Y654 of ȕ-catenin by tyrosine kinases (e.g. Bcr-Abl, KIT, Flt3 and Src) facilitates its activity to start its downstream target genes (e.g., c-Myc, cyclin D1 and Axin2) in leukemia cells (15, (36) (37) (38) (39) . We evaluated the impact of ponatinib on ȕ-catenin and its effector molecules. The Western blotting analysis showed a dose-and time-dependently decreased total level of ȕ-catenin in ponatinib-treated cells (Fig. 5A) . Because the stability of ȕ-catenin is tightly regulated by GSK3ȕ in the canonical Wnt/ȕ-catenin signaling pathway, we examined and discovered that ponatinib inhibited the phosphorylation at S9 in GSK3ȕ (inactive GSK3ȕ) without changing its phosphorylation at Y216 (active GSK3ȕ) (Fig. 5A) (40) . Therefore, the ponatinib mediated decline in ȕ-catenin was unlikely to be through GSK3ȕ. This notion was further supported by the finding that proteasome inhibitor MG132 did not reverse the ponatinib-mediated decline in ȕ-catenin (data not shown).
Tyrosine kinase Bcr-Abl was reported to control the degree of β-catenin protein stabilization in leukemia cells (36) . It remains elusive whether there is similar interaction between KIT and β-catenin. We did notice a concomitant reduction in the phosphorylation at Y654 of ȕ-catenin in the ponatinib-treated cells (Fig. 5A) .
Ponatinib downregulates the expression of ȕ-catenin by accelerating its turnover rate
To unveil the underlying regulation of ponatinib in ȕ-catenin, HMC-1.2 cells were incubated with ponatinib for 12 hours, followed by adding cycloheximide (CHX) to the cells for different durations. The expression levels of ȕ-catenin were detected by Western blotting analysis. The data showed that ponatinib accelerated the turnover of ȕ-catenin (Fig. 5B) .
Ponatinib decreases ȕ-catenin both in cytoplasm and nucleus
The change in total ȕ-catenin in ponatinib-treated cells prompted us to examine whether ponatinib affected the subcellular distribution of ȕ-catenin. blotting analysis. The results showed that ponatinib remarkably reduced ȕ-catenin both in the cytoplasmic and nuclear fractions (Fig. 5C ). This effect of ponatinib was further confirmed by immunofluorescence microscopy (Fig. 5D ). To quantitatively measure this effect, we analyzed the intracellular activated ȕ-catenin in cells with flow cytometry, and found that the percentage of ABC (active-ȕ-catenin)-positive cells was significantly decreased (from ∼ 46% to 23%, control vs. ponatinib, respectively, Supplementary Fig. S2A ).
Ponatinib inhibits expression of downstream targets
Consistently with the decline of ȕ-catenin, the expression of its key downstream targets such as c-Myc and cyclin D1 was also decreased in the ponatinib-treated cells (Fig. 5A) . Further, we confirmed this effect by measuring the expression of Axin2 which is believed a relatively exclusive target gene of ȕ-catenin (41) . The qRT-PCR analysis indicated that ponatinib dose-dependently decreased the mRNA levels of Axin2 ( Supplementary Fig. S2B ).
Ponatinib inhibits DNA binding of TCF
A principal function of ȕ-catenin in cancer lies in its ability to bind TCF/LEF family transcription factors to activate gene expression (42) . We employed EMSA to evaluate the inhibitory effect of ponatinib on the binding of TCF to DNA. HMC-1. electrophoresed and detected with a TCF probe. Ponatinib induced a dose-and time-dependent decline in levels of TCF-DNA complex (Fig. 5E ).
Ponatinib represses TCF-dependent reporter gene transcription
To verify the effect of ponatinib on the TCF/LEF transcriptional function, we performed a dual-luciferase reporter assay. HMC-1.2 cells were co-transfected with plasmids of pTOPflash (or pFOPflash) and Renilla luciferase, exposed to increasing concentrations of ponatinib, and subjected to the dual-luciferase reporter assay. The data showed that ponatinib significantly reduced the luciferase activity relative to control cells (Fig. 5F ). silencing of ȕ-catenin alone was not sufficient to trigger apoptosis. Therefore, ȕ-catenin might play a promoting role in apoptosis induced by ponatinib.
Ponatinib curbs the growth of xenografted HMC-1.2 cells in nude mice
We assessed the in vivo effect of ponatinib with a nude mouse xenograft model.
The tumor growth curves (the estimated tumor size calculated from the tumor dimension over time) were significantly inhibited by ponatinib (Fig. 6A) . The tumors did not regrow during the drug administration (Fig. 6A) . The weights of tumors were significantly lower in the treated group than in placebo group (Fig. 6B) . The body weights of mice were stable, with no significant difference between the placebo and treatment group (data not shown). In addition, immunohistochemical staining showed that the levels of p-KIT, ȕ-catenin, and Mcl-1 were appreciably decreased in the xenografted tumor tissues from ponatinib-treated mice (Supplementary Fig. S3 ).
Additionally, the decrease of Ki67 staining revealed that ponatinib prominently depressed the proliferation of xenografted HMC-1.2 cells (Supplementary Fig. S3 ).
We further detected the in vivo effect of ponatinib on KIT and its downstream molecules. Western blotting analysis indicated that the levels of ȕ-catenin, p-KIT and its downstream signaling were extensively deceased in ponatinib-treated tumors (Fig.   6C ). In aggregate, the results showed that ponatinib inhibited xenografted imatinib-resistant HMC-1. 
mast cell leukemia
Injection of murine mastocytoma cell line P815 carrying D814Y KIT into syngeneic DBA/2 mice is a useful model for testing potential drugs against D816V KIT (the homologous D814Y mutation). We employed this model to evaluate the efficacy of ponatinib against D816V KIT. 1×10 6 P815 cells were injected into the vena caudalis of DBA/2 mice. The next day, mice were randomized into two groups:
placebo (DMSO-containing medium) and ponatinib (20 mg/kg, oral gavage once daily). A group of healthy mice was also examined as a normal control. The survival was monitored for 20 days after cell injection and analyzed by the Kaplan-Meier survival curve (Fig. 6D) . The median survival was 10 and 18 days in mice treated with placebo and ponatinib, respectively (P<0.001, log-rank test).
For a cross-sectional analysis, when the placebo group seemed moribund on day 10 after cell injection, all three groups of mice were sacrificed. Placebo group exhibited significant increase in the WBC count and decrease in the platelet and RBC counts in the peripheral blood specimens (Supplementary Fig. S4 ). Compared to ponatinib group, mice in placebo group had increased size and weight of liver and spleen (Fig. 6E) . To analyze the infiltration of mast cells, nucleated cells obtained from spleens were analyzed by flow cytometry for the proportion of mast cells that expressed both CD45 (pan-leukocyte antigen) and CD117 . As shown in Fig. 6F , mice treated with ponatinib had a lower proportion of CD45+CD117+ cells. The decreased infiltration in the liver and spleen in the ponatinib-treated mice was confirmed by light microscopy (Fig. 6G) . The signal pathways were also inhibited after treatment of 
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Page 22 of 31 ponatinib as indicated by Western blotting (Fig. 6H) . In summary, our in vivo data suggest that ponatinib may be an important candidate for treating mastocytosis patients carrying the D816V KIT mutation.
Discussion
Previous studies have shown in vitro activity of ponatinib against tyrosine kinases such as Bcr-Abl, FIP1L1-PDGFRĮ, KIT Y823D, and FGFR1 (22) . Here, we validated the in vivo and in vitro activity of ponatinib against human mast cells to support further clinical evaluation of ponatinib in imatinib-resistant SM patients.
Oncogenic KIT has been reported to promote mast cell growth via downstream targets (e.g. Stat3/5, Akt and Erk1/2) (12). Abrogation of PI3K signaling cascade was found to critically impair the transformation capability of cells bearing D816V KIT (12) . Our results demonstrate that ponatinib decreases the phosphorylation of KIT at tyrosine 568/570 residues and its downstream signaling crucial to cell proliferation and survival including Stat3/5, Akt and Erk1/2. Furthermore, ponatinib induces comparable cell death rates in the two cell lines as analyzed by flow cytometry.
Interestingly, two bands were observed when doing immunoblotting with cyclin D1 antibody in ponatinib-treated cells (Fig. 5A) . The lower bands became stronger, coinciding with the kinetic apoptosis after treatment, which prompted one to speculate that cyclin D1 might have been cleaved by caspase(s). However, this hypothesis will need testing in the future. 
